Sage Therapeutics, Inc. (SAGE) Receives Average Rating of “Buy” from Brokerages

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have received a consensus recommendation of “Buy” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $89.64.

A number of equities analysts recently commented on SAGE shares. Leerink Swann reiterated an “outperform” rating and set a $97.00 price target (up previously from $90.00) on shares of Sage Therapeutics in a report on Tuesday, June 20th. ValuEngine upgraded Sage Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Stifel Nicolaus started coverage on Sage Therapeutics in a report on Wednesday. They set a “buy” rating and a $104.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and set a $82.00 price target on shares of Sage Therapeutics in a report on Tuesday, June 13th. Finally, Canaccord Genuity set a $110.00 price objective on Sage Therapeutics and gave the stock a “buy” rating in a report on Saturday, August 5th.

Sage Therapeutics (SAGE) traded up 1.28% on Friday, reaching $84.68. The company’s stock had a trading volume of 252,288 shares. Sage Therapeutics has a 52-week low of $35.02 and a 52-week high of $90.43. The firm has a 50-day moving average price of $81.82 and a 200 day moving average price of $70.17. The firm’s market capitalization is $3.17 billion.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing analysts’ consensus estimates of ($1.63) by $0.25. During the same period last year, the company posted ($1.08) earnings per share. Equities analysts anticipate that Sage Therapeutics will post ($7.38) earnings per share for the current fiscal year.

WARNING: “Sage Therapeutics, Inc. (SAGE) Receives Average Rating of “Buy” from Brokerages” was posted by Rincon Hill News and is owned by of Rincon Hill News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://rinconhillneighbors.org/2017/08/13/sage-therapeutics-inc-sage-given-consensus-rating-of-buy-by-analysts-updated.html.

Several large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. acquired a new stake in Sage Therapeutics during the fourth quarter worth $538,000. State Board of Administration of Florida Retirement System increased its position in shares of Sage Therapeutics by 7.1% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 12,056 shares of the biopharmaceutical company’s stock valued at $616,000 after buying an additional 800 shares in the last quarter. Norges Bank purchased a new position in shares of Sage Therapeutics during the fourth quarter valued at approximately $12,452,000. Teachers Advisors LLC increased its position in shares of Sage Therapeutics by 15.0% in the fourth quarter. Teachers Advisors LLC now owns 49,296 shares of the biopharmaceutical company’s stock valued at $2,517,000 after buying an additional 6,419 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of Sage Therapeutics by 7,004.1% in the first quarter. Bank of Montreal Can now owns 12,006 shares of the biopharmaceutical company’s stock valued at $853,000 after buying an additional 11,837 shares in the last quarter.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.